- 专利标题: METHOD OF TREATING AUTOIMMUNE DISEASE WITH LYMPHOCYTE ANTIGEN CD5-LIKE (CD5L) PROTEIN
-
申请号: US17226506申请日: 2021-04-09
-
公开(公告)号: US20210317186A1公开(公告)日: 2021-10-14
- 发明人: Vijay K. Kuchroo , Chao Wang , Aviv Regev , Karthik Shekhar
- 申请人: The Brigham and Women's Hospital, Inc. , The Broad Institute, Inc. , Massachusetts Institute of Technology
- 申请人地址: US MA Boston; US MA Cambridge; US MA Cambridge
- 专利权人: The Brigham and Women's Hospital, Inc.,The Broad Institute, Inc.,Massachusetts Institute of Technology
- 当前专利权人: The Brigham and Women's Hospital, Inc.,The Broad Institute, Inc.,Massachusetts Institute of Technology
- 当前专利权人地址: US MA Boston; US MA Cambridge; US MA Cambridge
- 主分类号: C07K14/705
- IPC分类号: C07K14/705 ; A61K38/20 ; A61K38/17 ; A61P37/00 ; A61P1/00 ; A61P35/00 ; A61K39/395 ; A61K45/06 ; C07K14/54 ; C07K16/24 ; C07K16/28 ; C12N15/113
摘要:
Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.